SK3 Group (OTC Pink: SKTO) Is Seeking to Survey Qualified California Medical Marijuana Patients for Its Soon to Be Released D...
February 28 2014 - 8:05AM
Marketwired
LOS ANGELES, CA-(Marketwired - Feb 28, 2014) - Medical Greens, a
subsidiary of SK3 Group (OTC Pink: SKTO) is seeking qualified
California medical marijuana patients to receive a free sample of
its new, non-psychoactive medical cannabis product, Dharmanol
Citrolene, developed by its Berkeley Bio-Organic Research
Laboratory.
Containing many of the medicinal elements of medical marijuana
in their non-psychoactive form, Dharmanol Citrolene provides many
of the benefits that scientists are ascribing to medical cannabis,
without the high associated with eating or smoking marijuana.
Dharmanol Citrolene contains CBD, a non-psychoactive "chemical
cousin" to THC, the element in marijuana that makes people high or
stoned. In addition, it contains phyto-cannabinoids in their
non-psychoactive carboxylate form. It also contains d-limonene, a
medicinal element found in cannabis, known as a terpene.
D-limonene has been shown to have a relaxing, anti-anxiety,
anti-spasmodic effect. This is because it binds to the same
receptors in the human body as do the pharmaceutical synthetics
Valium and Xanax. Dharmanol Citrolene contains a healthy dose
of organically-sourced d-limonene. Although the d-limonene
used in Dharmanol Citrolene is chemically identical to that
produced by the cannabis/hemp plant, it is actually sourced from
the rind of citrus fruits.
Interestingly, research has shown d-limonene to have many
properties that are similar to cannabis in their interaction with
cancer. Sloan Kettering Cancer Center lists 19 very promising
studies using this powerful natural medicine.
http://www.mskcc.org/cancer-care/herb/d-limonene.
To participate in the Company's survey, an individual must be a
medical cannabis patient with a valid physician recommendation and
live in the State of California in one of the zip codes currently
served by Pharmajanes.com. To see if you qualify, go to the website
and check out the section labeled "Dharmanol Citrolene
Promotion." Starting this upcoming Wednesday, March 5, 2014,
individuals requesting the promotional product during the first 30
days, while supplies last, will receive a 2-pack of the
product.
Patients participating in the survey will be asked to complete a
short questionnaire about their use of the product which will
assist the Company in developing or improving its offerings.
Dharmanol Citrolene will be available for sale soon after that
through Pharmajanes and many dispensaries throughout
California.
Mr. Artemus Mayor, President of SK3 Group said, "Now that our
Pharmajanes site is up and running, and we are filling orders for
our Dharmanol product, we are pleased to be initiating distribution
for this important product through our Pharmajanes
platform. While Dharmanol Citrolene will only be available to
participants in the promotion for the next several weeks, we intend
to have the product available to all qualified patients soon,
either through our Pharmajanes platform, or through their local
dispensary."
About AEGY PharmaJanes™ is an online ordering platform allowing
medical marijuana patients to order, process and pay for their
authorized needs, in a simple, safe and secure ordering and payment
interface. Simple Prepay is a merchant payment solution developed
to offer a convenient payment solution to medical cannabis
dispensaries, collectives, and delivery services. PharmaJanes also
is the exclusive online marketing platform for Medical Greens, a
subsidiary of SK3 Group, Inc. (OTC Pink: SKTO).
About SKTO SK3 is a healthcare logistics and fulfillment
consultancy focused on the delivery of alternative care and
medicine. With seasoned management, breakthrough technology and
best practices, SK3 brings standardization and transparency to this
rapidly growing segment of the alternative care field.
FDA Statement The statements in this document have not been
evaluated or approved by the FDA. The products and statements
referenced in this document are not intended to diagnose, treat,
cure, or prevent any disease.
Safe Harbor Statement This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based on the
current plans and expectations of management and are subject to a
number of uncertainties and risks that could significantly affect
the company's current plans and expectations, as well as future
results of operations and financial condition. A more extensive
listing of risks and factors that may affect the company's business
prospects and cause actual results to differ materially from those
described in the forward-looking statements can be found in the
reports and other documents filed by the company with the
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact
information Medical GreensInvestors@medicalgreens.com Investor
Relations
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Mar 2024 to Apr 2024
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Apr 2023 to Apr 2024